

References

S-121

1. InterQual® Level of Care Criteria 2021. Acute Care Adult. McKesson Health Solutions, LLC.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Hepatobiliary cancers. Version 2022.
3. Marot A, Dubois M, TreÂpo E, Moreno C, Deltenre P. Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. *PLoS ONE*. 2018;13(1).
4. Utako P, Emyoo T, Anothaisintawee T, et al. Clinical outcomes after liver transplantation for hepatorenal syndrome: A systematic review and meta-analysis. *BioMed Research Intl*. 2018.
5. Hamilton EC, Balogh J, Nguyen DT, et al. Liver transplantation for primary hepatic malignancies of childhood: The UNOS experience. *J Pediatric Surg*. 2018;53(1):163-169.
6. Firl DJ, Kimura S, McVey J, et al. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with HALTHCC improves ablate and wait strategy. *Hepatology*. 2018.
7. Yadav DK, Chen W, Bai X, et al. Salvage liver transplant versus primary liver transplant for patients with hepatocellular carcinoma. *Ann Transplant*. 2018;3;23:524-545.
8. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Neuroendocrine and Adrenal Tumors. Version 1.2022.
9. Luckett K, Kaiser TE, Bari K, et al. Use of hepatitis c virus antibody-positive donor livers in hepatitis C nonviremic liver transplant recipients. *J Am Coll Surg*. 2019;228(4):560-567.
10. Saberi B, Hamilton JP, Durand CM, et al. Utilization of hepatitis C virus RNA-positive donor liver for transplant to hepatitis C virus RNA-negative recipient. *Liver Transpl*. 2018;24(1):140-143.
11. Campos-Varela I, Agudelo EZ, Sarkar M, et al. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. *Transpl Infect Dis*. 2018;20(1).
12. Kwong AJ, Wall A, Melcher M, et al. Liver transplantation for hepatitis C virus (HCV) non-viremic recipients with HCV viremic donors. *Am J Transplant*. 2019;19(5):1380-1387.
13. Organ Procurement and Transplantation Network. Governance. Policies. Policy 9: Allocation of livers and liver-intestines. 04/01/2020.

14. American Association for the Study of Liver Diseases, American Society of Transplantation. Liver transplantation, evaluation of the adult patient. 2013; <https://www.aasld.org/publications/practiceguidelines>.
15. Black CK, Termanini KM, Aguirre O, et al. Solid organ transplantation in the 21st *Ann Transl Med*. 2018;6(20):409.
16. Gadiparthi C, Cholankeril G, Perumpail BJ, et al. Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. *World J Gastroenterol*. 2018;24(3):315-322.
17. Blumberg EA, Rogers CC. Solid organ transplantation in the HIV-infected patient: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. *Clin Transplant*. 2019;33(9):e13499.
18. American Association for the Study of Liver Diseases. Diagnosis and treatment of alcohol associated liver diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases. <https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30866>.
19. Yong JN, Lim WH, Ng CH, et al. Outcomes of nonalcoholic steatohepatitis after liver transplantation: an updated meta-analysis and systematic review [published online ahead of print, 2021]. *Clin Gastroenterol Hepatol*. 2021;S1542-3565(21)01226-X.
20. Cambridge WA, Fairfield C, Powell JJ, et al. Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma. *Ann Surg*. 2021;273(2):240-250.
21. Ziogas IA, Giannis D, Economopoulos KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: A meta-analysis and meta-regression of survival rates. *Transplantation*. 2021;105(10):2263-2271.
22. Hue JJ, Rocha FG, Ammori JB, et al. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: An analysis of the National Cancer Database. *J Surg Oncol*. 2021;123(4):949-956.
23. Salimi J, Jafarian A, Fakhari N, et al. Study of re-transplantation and prognosis in liver transplant center in Iran. *Gastroenterol Hepatol Bed Bench*. 2021;14(3):237-242.
24. Bouari S, Rijkse E, Metselaar HJ, et al. A comparison between combined liver kidney transplants to liver transplants alone: A systematic review and meta-analysis. *Transplant Rev (Orlando)*. 2021;35(4):100633.
25. Tang W, Qiu JG, Cai Y, Cheng L, Du CY. Increased surgical complications but improved overall survival with adult living donor compared to deceased donor liver transplantation: A systematic review and meta-analysis. *Biomed Res Int*. 2020;2020:1320830.

26. Kapila N, Menon KVN, Al-Khalloufi K, et al. Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus-negative recipients: A real-world experience. *Hepatology*. 2020;72(1):32-41.
27. Cotter TG, Paul S, Sandıkçı B, et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: Outcomes following liver transplant of HCV-viremic donors. *Hepatology*. 2019;69(6):2381-2395.
28. Sobotka LA, Mumtaz K, Wellner MR, et al. Outcomes of hepatitis C virus seropositive donors to hepatitis C virus seronegative liver recipients: A large single center analysis. *Ann Hepatol*. 2021;24:100318.
29. Aqel B, Wijarnpreecha K, Pungpapong S, et al. Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. *J Hepatol*. 2021;74(4):873-880.